Empagliflozin/Metformin Hydrochloride Tablet 5/1000 mg
Empagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kuju Pharmaceutical Co., Ltd.
MFDS item code 202201394 · Approved 2022.04.04
Improvement of glycemic control in adults with type 2 diabetes
This medication is suitable as an adjunct to diet and exercise in improving blood sugar control for adult patients with Type 2 diabetes. It is particularly given to patients whose blood sugar is not sufficiently controlled, and clinical information from specialists is needed regarding the risk of cardiovascular events in patients with cardiovascular disease. This medication effectively aids in improving blood sugar control.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse effects associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication is an antidiabetic agent used to lower blood sugar. It may cause a rare but serious side effect called lactic acidosis, and should not be used in patients with impaired kidney function or liver function. Caution is also required when used with insulin or sulfonylurea medications due to the risk of hypoglycemia. It should not be administered in patients with moderate or greater impairment of kidney function or conditions that may cause acute kidney injury. This medication should be temporarily discontinued during situations such as before and after surgery, severe infections, dehydration, or acute myocardial infarction. It is safer not to use this medication during pregnancy or breastfeeding. During treatment, regular monitoring of kidney function and blood creatinine levels is necessary. Patients at risk of fluid loss should pay attention to dehydration symptoms and may need to temporarily suspend the medication if necessary. Side effects may include gastrointestinal disturbances, hypoglycemia, urinary tract infections, genital infections, increased urination, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, abnormal liver function tests, taste disturbances, itching, rash, urticaria, angioedema, difficulty urinating, thirst, increased serum lipids, increased blood creatinine levels, increased hematocrit, reduced and deficiency of Vitamin B12, reduced fluid volume, headaches, dizziness, postural dizziness, memory disturbances, drowsiness, fatigue, fever. Additionally, this medication may reduce Vitamin B12 levels, so patients on long-term treatment should check their blood Vitamin B12 concentration. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided during treatment. This medication may interact with other medications, and patients should inform their healthcare provider of any other medications they are taking. Elderly patients have an increased risk of kidney function decline and fluid loss, so dosage adjustments and careful monitoring are necessary. In case of overdose, professional treatment such as hemodialysis may be required, and patients should seek medical attention immediately. This medication has not been established as safe and effective in children; therefore, it is not recommended for patients under 18 years of age. Finally, this medication should be stored out of reach of children and maintained in its original container to preserve quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and safety over time.
Biconvex oval film-coated tablet with a yellowish brown color
10 tablets/box [10 tablets/PPT X1], 60 tablets/box [10/PPT X6], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kuju Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.